Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS ...

The drug was developed from methylene blue, a medicine previously used to treat malaria. Professor Alistair Burns, former NHS clinical director for dementia ... "After no new therapies for ...

At the end of this year, we understand different risk factors for dementia and potential treatments more deeply than ever before. Researchers working on the Lancet Commission study, part-funded by ...

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.